CoTherix

From Wikipedia, the free encyclopedia
Jump to: navigation, search


CoTherix, Inc.
Former type Subsidiary
Industry Pharmaceutical
Fate acquired by Actelion
Founded 2000
Defunct January 9, 2007 (2007-01-09)
Headquarters South San Francisco, California
Key people Donald J. Santel, CEO & Director
Products Ventavis
Revenue $63 million USD
Employees 100
Website www.cotherix.com

CoTherix, Inc. was a biopharmaceutical company located in South San Francisco, California. CoTherix focused on licensing, developing, and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. The company, formerly known as Exhale Therapeutics, Inc., was founded in February 2000 by Gerard Turino, MD, a past president of the American Thoracic Society, and Jerome Cantor, MD, a pulmonary pathologist.

CoTherix's commercial product was "Ventavis (iloprost)", an inhaled therapy for pulmonary artery hypertension (PAH). It was approved by the United States Food and Drug Administration in December 2004, two months after the company's initial public offering of 5 millions shares of common stock.

CoTherix inlicensed Fasudil from Asahi Kasei and its commercialization rights in the U.S. and Europe.

On November 20 2006, CoTherix agreed to be purchased for $420 million in cash by Actelion of Basel, Switzerland. On January 9, 2007, the deal closed with Actelion paying $13.50 for each share of CoTherix stock.

External links[edit]